Tsung-Ju Chuang1,2, Yu-Hsun Wang3, James Cheng-Chung Wei4,5,6, Chih-Jung Yeh2. 1. Division of Endocrinology and Metabolism, Department of Internal Medicine, National Defense Medical Center, Taichung Armed Forces General Hospital, Taichung, Taiwan. 2. School of Public Health, Chung Shan Medical University, Taichung, Taiwan. 3. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan. 4. Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan. 5. Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan. 6. Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
Abstract
Objectives: Gout is the most common form of inflammatory arthritis and was found to be independently associated with incident dementia in the elderly. However, the associations between anti-gout preparations and dementia were not well-studied. Methods: Data were collected from Taiwan's National Health Insurance Research Database (NHIRD). A 2005-2013 retrospective cohort study was conducted, and all investigated subjects were identified by International Statistical Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification. Conditional logistic regression was used to evaluate the odds ratio of dementia in relation to different gout preparations (benzbromarone, allopurinol, sulfinpyrazone, probenecid) and number of days of anti-gout preparation use, after adjustment for potential confounding variables. Results: A total of 3,242 gout patients with and without dementia were selected from the NHIRD and included in the final analysis after 1:1 matching for age, gender, and diagnosis year of gout. In the anti-gout preparations, only use of Benzbromarone decreased the risk of dementia (adjusted OR, 0.81; 95% CI, 0.68-0.97). The result of the subgroup analysis revealed a trend toward a lower risk of dementia with longer use of benzbromarone. Use of benzbromarone for ≥180 days showed a significantly lower risk of dementia (adjusted OR, 0.72; 95% CI, 0.58-0.89). Moreover, the protective effect was more pronounced in males compared with females. Conclusion: This cohort study reveals that gout patients taking benzbromarone are at a decreased risk of developing incident dementia, especially with longer use and in male. Further prospective trials are warranted to confirm our findings.
Objectives:Gout is the most common form of inflammatory arthritis and was found to be independently associated with incident dementia in the elderly. However, the associations between anti-gout preparations and dementia were not well-studied. Methods: Data were collected from Taiwan's National Health Insurance Research Database (NHIRD). A 2005-2013 retrospective cohort study was conducted, and all investigated subjects were identified by International Statistical Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification. Conditional logistic regression was used to evaluate the odds ratio of dementia in relation to different gout preparations (benzbromarone, allopurinol, sulfinpyrazone, probenecid) and number of days of anti-gout preparation use, after adjustment for potential confounding variables. Results: A total of 3,242 goutpatients with and without dementia were selected from the NHIRD and included in the final analysis after 1:1 matching for age, gender, and diagnosis year of gout. In the anti-gout preparations, only use of Benzbromarone decreased the risk of dementia (adjusted OR, 0.81; 95% CI, 0.68-0.97). The result of the subgroup analysis revealed a trend toward a lower risk of dementia with longer use of benzbromarone. Use of benzbromarone for ≥180 days showed a significantly lower risk of dementia (adjusted OR, 0.72; 95% CI, 0.58-0.89). Moreover, the protective effect was more pronounced in males compared with females. Conclusion: This cohort study reveals that goutpatients taking benzbromarone are at a decreased risk of developing incident dementia, especially with longer use and in male. Further prospective trials are warranted to confirm our findings.
Authors: Elizabeth E Devore; Francine Grodstein; Frank J A van Rooij; Albert Hofman; Meir J Stampfer; Jacqueline C M Witteman; Monique M B Breteler Journal: Arch Neurol Date: 2010-07
Authors: F Perez-Ruiz; A Alonso-Ruiz; M Calabozo; A Herrero-Beites; G García-Erauskin; E Ruiz-Lucea Journal: Ann Rheum Dis Date: 1998-09 Impact factor: 19.103
Authors: H Ralph Schumacher; Michael A Becker; Robert L Wortmann; Patricia A Macdonald; Barbara Hunt; Janet Streit; Christopher Lademacher; Nancy Joseph-Ridge Journal: Arthritis Rheum Date: 2008-11-15
Authors: John D FitzGerald; Nicola Dalbeth; Ted Mikuls; Romina Brignardello-Petersen; Gordon Guyatt; Aryeh M Abeles; Allan C Gelber; Leslie R Harrold; Dinesh Khanna; Charles King; Gerald Levy; Caryn Libbey; David Mount; Michael H Pillinger; Ann Rosenthal; Jasvinder A Singh; James Edward Sims; Benjamin J Smith; Neil S Wenger; Sangmee Sharon Bae; Abhijeet Danve; Puja P Khanna; Seoyoung C Kim; Aleksander Lenert; Samuel Poon; Anila Qasim; Shiv T Sehra; Tarun Sudhir Kumar Sharma; Michael Toprover; Marat Turgunbaev; Linan Zeng; Mary Ann Zhang; Amy S Turner; Tuhina Neogi Journal: Arthritis Care Res (Hoboken) Date: 2020-05-11 Impact factor: 4.794
Authors: Ross Luu; Silvana Valdebenito; Eliana Scemes; Antonio Cibelli; David C Spray; Maximiliano Rovegno; Juan Tichauer; Andrea Cottignies-Calamarte; Arielle Rosenberg; Calude Capron; Sandrine Belouzard; Jean Dubuisson; Djillali Annane; Geoffroy Lorin de la Grandmaison; Elisabeth Cramer-Bordé; Morgane Bomsel; Eliseo Eugenin Journal: iScience Date: 2021-11-19